Related Experiment Video
Updated: Aug 4, 2026
07:59
A High Throughput MHC II Binding Assay for Quantitative Analysis of Peptide Epitopes
Published on: March 25, 2014
Antibody like peptidomimetics as large scale immunodetection probes
1252 John Morgan Building, Department of Pathology and Laboratory Medicine, Abramson Family Cancer Research, University of Pennsylvania, 36th and Hamilton Walk, Philadelphia, PA 19104-6082, USA.
Cellular and Molecular Biology (Noisy-Le-Grand, France)
|July 31, 2003
Summary
Researchers developed antibody-like binding peptidomimetics (ABiPs) as smaller, engineered alternatives to monoclonal antibodies (mAbs). These novel molecules show promise for antigen detection and therapeutic development, overcoming limitations of traditional antibody production.
Area of Science:
- Biochemistry
- Molecular Biology
- Immunology
Background:
- Monoclonal antibodies (mAbs) are vital tools in research and therapeutics but face production challenges.
- Limitations in mAb production hinder the development of diverse and therapeutic quantities.
- Existing mAbs have constraints in clinical applications and basic research.
Purpose of the Study:
- To develop a novel methodology for creating smaller, engineered antibody alternatives.
- To engineer peptidomimetics with enhanced serum half-life and affinity.
- To create a versatile platform for antigen detection, therapeutics, and drug development.
Main Methods:
- Developed a methodology to reduce antibodies into smaller peptidomimetics.
- Engineered novel "antibody-like binding peptidomimetics" (ABiPs).
- Created an Anti-Her2/neu peptidomimetic (AHNP) and fused it with streptavidin for immunodetection probes.
Main Results:
- Developed AHNP, a mimic of Herceptin, for advanced breast cancer therapy research.
- Utilized AHNP-streptavidin fusion proteins for highly sensitive Her2/neu antigen detection via immunodetection amplification technique (IDAT).
- Demonstrated detection of Her2/neu antigen at extremely low concentrations.
Conclusions:
- A diverse library of ABiPs can serve as a viable alternative to monoclonal antibody panels.
- ABiPs offer potential applications in target validation, antigen detection, and therapeutics.
- ABiPs represent a promising platform for future drug development.
Related Concept Videos
01:10Antibody Structure
Overview
Antibodies, also known as immunoglobulins (Ig), are essential players of the adaptive immune system. These antigen-binding proteins are produced by B cells and make up 20 percent of the total blood plasma by weight. In mammals, antibodies fall into five different classes, which each elicits a different biological response upon antigen binding.
The Y-Shaped Structure of Antibodies Consists of Four Polypeptide Chains
Antibodies consist of four polypeptide chains: two identical heavy...
Antibodies, also known as immunoglobulins (Ig), are essential players of the adaptive immune system. These antigen-binding proteins are produced by B cells and make up 20 percent of the total blood plasma by weight. In mammals, antibodies fall into five different classes, which each elicits a different biological response upon antigen binding.
The Y-Shaped Structure of Antibodies Consists of Four Polypeptide Chains
Antibodies consist of four polypeptide chains: two identical heavy...
01:20Immunoprecipitation
Immunoprecipitation, or IP, is a widely used technique that employs protein-antibody interactions to isolate proteins or protein complexes in their native state for studying protein-protein interactions, quaternary structures, or supramolecular complexes. Various modifications of the technique, including chromatin IP, cross-linking IP, and fluorescence IP, are commonly used.
Chromatin Immunoprecipitation
Chromatin immunoprecipitation, also known as ChIP, is used to study protein-DNA or...
Chromatin Immunoprecipitation
Chromatin immunoprecipitation, also known as ChIP, is used to study protein-DNA or...